This site is intended for US Healthcare Professionals only
Prior authorization is a process used to determine if a prescribed procedure, service, or medication will be covered. This process does not guarantee payment. A prior authorization is not pre-determined by a health plan. Prior authorizations may be required for Axumin and/or PET imaging.
Predetermination is determination of the reimbursement amount from a third party before a health care service is performed. It does not guarantee payment.
NOTE: The provider has the responsibility to ensure correct prior authorization, appeal and denial policies are followed. Providers must ensure they accurately complete and submit necessary information to payers. Verify benefits, eligibility, coverage and requirements for prior authorization or predetermination.
The information on this website contains factual information and is not intended to be legal or coding advice. Blue Earth does not guarantee coverage or reimbursement for Axumin. The existence of billing codes does not guarantee coverage and payment. Payer policies vary and may change without notice. It is the provider's responsibility to determine and submit accurate information on claims. This includes submitting proper codes, modifiers, charges, and invoices for the services that were rendered. It is the provider's responsibility to ensure that all information on a claim is accurate. It is the provider's responsibility to check with the payer to determine whether the information contained on the claim is accurate. It is the responsibility of the provider to document the medical necessity of Axumin in the medical record.
Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
Please see Axumin full Prescribing Information.